That seems to be the called for test, but I believe that the line in the sand is clear at 4 & 12 weeks= 24 weeks total SOC
If detected, even if it is not quantifiable.... the recommended is 48 weeks. Keep in mind that there are many many vials of blood in a persons total some of blood in ones system (not to mention some that could reside in tissue) It doesn't take but a few virons to repopulate an infection.
The issue is that one is positive, even though it is very low. That signals that both the PI, the SOC and the innate immune response have not been able to eliminate the virus.....yet. What probably, almost certainly what remains are somewhat hardier, more resistant virii.
I think it's a good idea to see if you can retest any remaining blood from the positive draw. Lacking that another PCR. Depending upon the doctor and the test used I believe that some doctors have misread/misinterpreted the results. Make sure that they are clear on whether you are positive or not, get a hard copy of the result, and knowing that the results are based upon an amplification process ask about getting a subsequent PCR.
There are some doctors who are very familiar with the drugs, the PCR's and the interpretation of results. I've seen some that are less so and sometimes the results fall short of making such a critical test crystal clear; detected or
undetected.
===============================
http://www.ncbi.nlm.nih.gov/pubmed/22095516Hepatology. 2011 Nov 16. doi: 10.1002/hep.24791. [Epub ahead of print]
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.
Harrington PR, Zeng W, Naeger LK.
Source
Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993.
Patrick.Harrington@fda.hhs.gov.
Abstract
Boceprevir- and telaprevir-based treatments for chronic hepatitis C virus (HCV) infection use specific response-guided therapy (RGT) guidelines. Eligibility for shortened treatment duration is based on achieving Undetectable HCV RNA early during treatment. It is unclear whether a detected HCV RNA level that is below the assay lower limit of quantitation (Detectable/BLOQ) is comparable to an Undetectable HCV RNA level, particularly regarding RGT decision making.
We analyzed data from boceprevir and telaprevir clinical trials to obtain a comprehensive understanding of the frequency and clinical relevance of Detectable/BLOQ HCV RNA measurements. In Phase 3 trials P05216 (boceprevir), C216 (telaprevir) and 108 (telaprevir), Detectable/BLOQ levels were reported for approximately 10-20% of all on-treatment HCV RNA measurements. In P05216 and C216, subjects with Detectable/BLOQ HCV RNA, on average, had a reduced sustained virologic response (SVR) rate compared to subjects with Undetectable HCV RNA at the same on-treatment timepoint.
At key RGT timepoints (Week 8 for boceprevir, Week 4 for telaprevir), subjects with Detectable/BLOQ HCV RNA had an approximately 20% lower SVR rate compared to subjects with Undetectable HCV RNA, and this difference widened for later on-treatment time points. A similar trend was observed for Study 108, but the differences in SVR rates were more modest, which may be explained by a higher frequency of reported Detectable/BLOQ results. Analyses of Phase 2 boceprevir and telaprevir trials indicated subjects with Detectable/BLOQ HCV RNA at RGT timepoints benefited from extended treatment duration.
CONCLUSIONS: During boceprevir- and telaprevir-based treatment, subjects with Detectable/BLOQ HCV RNA had a reduced virologic response compared to subjects with Undetectable HCV RNA. Eligibility for shortened treatment duration should be based on patients achieving Undetectable HCV RNA at RGT decision timepoints. (HEPATOLOGY 2011.).
Copyright © 2011 American Association for the Study of Liver Diseases.
PMID:
22095516 [PubMed - as supplied by publisher]
=========================
http://pi.vrtx.com/files/uspi_telaprevir.pdf(see section 2.1 -willy)For the purpose of assessing response-guided therapy eligibility at weeks 4 and 12 (see Table 1), an “undetectable” HCV-RNA result is required; a confirmed “detectable but below limit of quantification” HCV-RNA result should not be considered equivalent to an “undetectable” HCV-RNA result [see
Laboratory Tests (5.6)].